Skip to main content

Newly detected rapid eye movement associated sleep apnea after coronavirus disease 2019 as a possible cause for chronic fatigue: two case reports



Coronavirus disease 2019 has become a health problem spreading worldwide with pandemic characteristics since March 2020. Post coronavirus disease 2019 symptoms are more frequent than initially expected, with fatigue as an often-mentioned issue.

Case presentations

We describe a 32-year-old white male and a 55-year-old white female who suffered from post coronavirus disease 2019 fatigue syndrome. On polysomnography, rapid eye movement associated sleep apnea with an increased hypopnea index during rapid eye movement phases of 36.8 and 19.5 events per hour was found. Based on the patients’ burdensome fatigue symptoms, we initiated automatic positive airway pressure therapy, which diminished sleep apnea (rapid eye movement index: 0.0 in both patients) and, consequently, also the fatigue symptoms.


Since sleep apnea and coronavirus disease 2019 are both associated with fatigue, a screening for sleep apnea might be considered in coronavirus disease 2019 patients with fatigue syndrome.

Peer Review reports


The coronavirus disease 2019 (COVID-19) pandemic spread rapidly worldwide in early 2020. According to the German Robert Koch Institute, a person is considered to be recovered from COVID-19 if he or she does not show any symptoms (such as cough or fever) for at least 48 hours in combination with a negative nasopharyngeal swab test. However, it is not uncommon that secondary COVID-19 symptoms remain after the acute infection phase [1]. These include but are not limited to fatigue syndrome, cognitive impairments, or reduced stress management. Fatigue syndrome is particularly burdensome for many patients after surviving a COVID-19 infection. This applies to patients that received outpatient care as well as to patients that were hospitalized [2].

Case presentation #1

A 32-year-old white physician without any previous disease got infected with SARS-CoV-2 in April 2020. The patient is of athletic condition with a normal to slightly reduced body mass index (20.1 kg/m2) and had never reported fatigue symptoms, concentration problems, or cognitive impairment before his SARS-CoV-2 infection. Although the acute symptoms of the COVID-19 phase had eased during a recovery phase at home, the patient still perceived limitations of physical performance and reported difficulties in concentration. In addition, the patient described severe general fatigue symptoms following COVID-19 as the predominant burden. Since these symptoms persisted, the patient was referred to a pulmonary rehabilitation program at the Schön Klinik Berchtesgadener Land (Germany) in August 2020.

At baseline assessment, the patient had normal lung function [FEV1: 118% predicted, total lung capacity (TLC): 99% predicted, VC: 99% predicted] and diffusion capacity (DLCO: 101% predicted). Computed tomography of the thorax was without pathological findings. Regarding the fatigue syndrome, fasting cortisol as well as thyroid parameters were analyzed but found to be within normal ranges. Therefore, we decided to perform a polysomnography for further clarification. An increased apnea–hypopnea index (AHI) of 5.2 was observed only during the rapid eye movement (REM) phases including 36.8 hypopnea events per hour (Fig. 1). This sleep apnea led to nocturnal awakening of the patient with a concomitant sensation of choking. We associated this sleep apnea with the fatigue syndrome of the patient. As a therapeutic consequence, automatic positive airway pressure (APAP) therapy was initiated. The patient showed good adherence to the APAP therapy using a nasal pillow mask with a pressure support between 5 and 7 mbar.

Fig. 1

Polysomnography of case 1 without automatic positive airway pressure (a) and with automatic positive airway pressure (b). Pink peaks indicate events of REM-associated sleep apnea

After 11 days of APAP therapy, the polysomnography was repeated and showed that sleep apnea has disappeared completely (AHI 0.0, and 0 hypopnea events; Table 1 and Fig. 1). Besides, the patient reported improvements in his fatigue and the ability to concentrate.

Table 1 Parameters during polysomnography without and with the use of automatic positive airway pressure therapy in two cases after post COVID-19

Case presentation 2

A 55-year-old healthy white nurse got infected with SARS-CoV-2 in April 2020. The patient is of slightly obese condition with an increased body mass index (31.0 kg/m2) but had never reported fatigue symptoms, cognitive impairments, or sleep disorders before her SARS-CoV-2 infection. Although the acute symptoms of the COVID-19 phase had eased during a recovery phase at home, the patient still perceived ongoing severe general fatigue symptoms as the predominant burden. In addition, the patient reported difficulties in memory performance and amnestic dysphasia.

On admission to pulmonary rehabilitation in September 2020, the patient had almost normal lung function (FEV1: 91% predicted, TLC: 90% predicted, VC: 86% predicted) and diffusion capacity (DLCO: 90% predicted). Spiroergometry revealed slightly reduced exercise performance (87% predicted) but no evidence for cardioventilatory limitations or impairment in lung diffusion capacity during exercise. Further, a polysomnography was performed for further clarification. An apnea–hypopnea index (AHI) of 6.2 was observed only during the REM phases including 19.5 hypopnea events per hour. This sleep apnea led to nocturnal awakening of the patient associated with a burning sensation in the lungs. As a therapeutic consequence, automatic positive airway pressure (APAP) therapy was again initiated. The patient showed very good adherence to the APAP therapy using a full face mask with pressure support between 7 and 10 mbar.

After 7 days of APAP therapy, the polysomnography was repeated and showed that sleep apnea had disappeared almost completely (AHI 1.7, and 0 hypopnea events; Table 1). Furthermore, the patient reported improvements of her fatigue symptoms as well as her concentration and memory performance.

Discussion and conclusions

To the best of our knowledge, these are the first two reported cases of fatigue following COVID-19 that might be induced by sleep apnea during the REM phase. The patients suffered from self-reported severe general fatigue and concentration impairment. These clinical symptoms as well as the sleep apnea were diminished after initiating APAP therapy.

Both patients had no history of sleep apnea or any other risk factors (except for slight obesity in patient 2). Therefore, the sleep apnea events that occurred during the non-REM phases could have been associated with mild obesity hypoventilation syndrome without clinical relevance since the clinical symptoms of fatigue and cognitive impairment appeared only after SARS-CoV-2 infection. Interestingly, in both cases, sleep apnea occurred only during the REM phases. This is a phenomenon that is not common in other sleep-related disorders. It was shown in former studies that a SARS-CoV-2 infection leads to endotheliitis with immunogen-triggered embolisms [3]. Abnormalities were found also in neuroimaging, which revealed diffuse cerebral hyperintensities that are indicative of leukencephalopathy [4] and perfusion abnormalities [5]. Up to now, ischemic stroke is the only disease that is known to depress REM sleep [6]. Therefore, endotheliitis-induced perfusion defect might be an individual explanation for the disturbed sleeping profile in the current COVID-19 cases. However, this hypothesis needs to be investigated in further research.

In conclusion, in the current two cases, newly diagnosed sleep apnea during the REM phases with subsequent severe fatigue syndrome was observed following COVID-19. APAP therapy diminished sleep apnea completely. Furthermore, patients reported that the post-COVID-19 fatigue symptoms and their ability to concentrate have improved.

Though it is possible that COVID-19 infection and subsequent diagnosis of sleep apnea are unrelated and do not suggest causality, sleep apnea must be considered in the differential diagnosis of patients with post-COVID-19 fatigue syndrome.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.



Apnea–hypopnea index


Automatic positive airway pressure


Diffusion lung capacity for carbon monoxide

FEV1 :

Forced expiratory volume in 1 second


Rapid eye movement


Severe acute respiratory syndrome coronavirus 2

SpO2 :

Oxygen saturation


Total lung capacity


Vital capacity


  1. 1.

    Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5.

    CAS  Article  Google Scholar 

  2. 2.

    Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue. 2020;8:61–9.

    Google Scholar 

  3. 3.

    Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–40.

    Article  Google Scholar 

  4. 4.

    Egbert AR, Cankurtaran S, Karpiak S. Brain abnormalities in COVID-19 acute/subacute phase: a rapid systematic review. Brain Behav Immun. 2020;S0889–1591:31253–8.

    Google Scholar 

  5. 5.

    Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–70.

    Article  Google Scholar 

  6. 6.

    Korner E, Flooh E, Reinhart B, Wolf R, Ott E, Krenn W, et al. Sleep alterations in ischemic stroke. Eur Neurol. 1986;25(2):104–10.

    Article  Google Scholar 

Download references


We thank the two patients for providing informed consent to publish their medical cases.


Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information




AS discovered the cases; RK and RG drafted the manuscript; all authors contributed scientific discussion to the manuscript and approved the final version. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Andreas Rembert Koczulla.

Ethics declarations

Ethics approval and consent to participate

An approval from an ethics committee was not obtained since these case reports were collected retrospectively. However, written consent was obtained from both patients to publish their data anonymously in this case report.

Consent for publication

Written informed consent was obtained from the patients for publication of these case reports and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koczulla, A.R., Stegemann, A., Gloeckl, R. et al. Newly detected rapid eye movement associated sleep apnea after coronavirus disease 2019 as a possible cause for chronic fatigue: two case reports. J Med Case Reports 15, 211 (2021).

Download citation


  • COVID-19
  • Sleep apnea
  • REM phase
  • Fatigue syndrome
  • APAP
  • CPAP
  • Case report